Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience

Documenti analoghi

• Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma
  di: Ke Xu, et al.
  Pubblicazione: (2024)
• The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience
  di: Dipal Mehta, et al.
  Pubblicazione: (2025)
• Challenges in designing and running smouldering myeloma interventional clinical trials
  di: Catherine Lecat, et al.
  Pubblicazione: (2024)
• Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study
  di: Dipal Mehta, et al.
  Pubblicazione: (2025)
• Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England
  di: Sally Moore, et al.
  Pubblicazione: (2024)